<?xml version="1.0" encoding="utf-8"?>
<Label drug="Tekturna" setid="833c7a0b-5f64-4363-94d5-9a179049113a">
<Text><Section name="BOXED WARNING SECTION" id="34066-1">
WARNING: 

 FETAL TOXICITY 

 When pregnancy is detected, discontinue Tekturna as soon as possible. (5.1) 

 Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) 

 WARNING: FETAL TOXICITY 

 See full prescribing information for complete boxed warning. 

 When pregnancy is detected, discontinue Tekturna as soon as possible. ( 5.1 ) 

 Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. 
 ( 5.1 )</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2     DOSAGE AND ADMINISTRATION 

 Starting dose: 150 mg once daily with a routine pattern with regard to meals. If blood pressure remains uncontrolled titrate up to 300 mg daily. ( 2.1 ,  2.2 ) 
 Majority of effect of given dose attained in 2 weeks ( 2.1 ) 

 2.1     Hypertension 

 The usual recommended starting dose of Tekturna is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the daily dose may be increased to 300 mg. Doses above 300 mg did not give an increased blood pressure response but resulted in an increased rate of diarrhea. The antihypertensive effect of a given dose is substantially attained (85% to 90%) by 2 weeks. 

 2.2     Relationship to Meals 

 Patients should establish a routine pattern for taking Tekturna with regard to meals. High fat meals decrease absorption substantially [see Clinical Pharmacology (12.3)] .</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4     CONTRAINDICATIONS 

 Do not use aliskiren with ARBs or ACEIs in patients with diabetes [see Warnings and Precautions (5.2) and Clinical Studies (14.3)] . 

 Tekturna is contraindicated in patients with known hypersensitivity to any of the components [see Warnings and Precautions (5.3)] . 

 Do not use with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes. ( 4 ) 
 Hypersensitivity to any of the components. ( 4 )</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5     WARNINGS AND PRECAUTIONS 

 Avoid concomitant use with ARBs or ACEIs particularly in patients with renal impairment [creatinine clearance (CrCl) &lt;60 mL/min]. ( 5.2 , 5.4 ) 

 Anaphylactic Reactions and Angioedema. ( 5.3 )  

 Hypotension: Correct imbalances in volume and/or salt depleted patients. ( 5.4 ) 

 Impaired Renal Function: Monitor serum creatinine periodically. ( 5.5 ) 

 Hyperkalemia: Monitor potassium levels periodically. ( 5.6 ) 

 5.1     Fetal Toxicity 

 Pregnancy Category D 
 Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Tekturna as soon as possible [see Use in Specific Populations (8.1)] . 

 5.2     Renal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs 

 Tekturna is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension. In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications (4), Drug Interactions (7) and Clinical Studies (14.3)] . 

 5.3     Anaphylactic Reactions and Head and Neck Angioedema 

 Hypersensitivity reactions such as anaphylactic reactions and angioedema of the face, extremities, lips, tongue, glottis and/or larynx have been reported in patients treated with Tekturna and has necessitated hospitalization and intubation. This may occur at any time during treatment and has occurred in patients with and without a history of angioedema with ACEIs or angiotensin receptor antagonists. Anaphylactic reactions have been reported from postmarketing experience with unknown frequency. If angioedema involves the throat, tongue, glottis or larynx, or if the patient has a history of upper respiratory surgery, airway obstruction may occur and be fatal. Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. Prompt administration of subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and measures to ensure a patent airway may be necessary. 
 Discontinue Tekturna immediately in patients who develop anaphylactic reactions or angioedema, and do not readminister [see Dosage and Administration (2.1) and Contraindications (4)] . 

 5.4     Hypotension 

 Symptomatic hypotension may occur after initiation of treatment with Tekturna in patients with marked volume depletion, patients with salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system (RAAS). The volume or salt depletion should be corrected prior to administration of Tekturna, or the treatment should start under close medical supervision. 
 A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. 

 5.5     Impaired Renal Function 

 Monitor renal function periodically in patients treated with Tekturna. Changes in renal function, including acute renal failure, can be caused by drugs that affect the RAAS. Patients whose renal function may depend in part on the activity of the RAAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or nonsteroidal anti-inflammatory drug (NSAID), including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors), therapy may be at particular risk for developing acute renal failure on Tekturna [see Warnings and Precautions (5.2 Drug Interactions (7), and Use in Specific Populations (8.7) and Clinical Studies (14.3)] . Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function. 

 5.6     Hyperkalemia 

 Monitor serum potassium periodically in patients receiving Tekturna. Drugs that affect the RAAS can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications (4), Warnings and Precautions (5.2), and Clinical Studies (14.3)] , NSAIDs, or potassium supplements or potassium sparing diuretics. 

 5.7     Cyclosporine or Itraconazole 

 When aliskiren was given with cyclosporine or itraconazole, the blood concentrations of aliskiren were significantly increased. Avoid concomitant use of aliskiren with cyclosporine or itraconazole [see Drug Interactions (7)] .</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7     DRUG INTERACTIONS 

 Cyclosporine: Avoid coadministration of cyclosporine with aliskiren [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)] . 

 Itraconazole: Avoid coadministration of itraconazole with aliskiren [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)] . 

 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving aliskiren and NSAID therapy. 
 The antihypertensive effect of aliskiren may be attenuated by NSAIDs. 

 Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two drugs that inhibit the renin-angiotensin system do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min. Monitor blood pressure, renal function, and electrolytes in patients taking aliskiren and other agents that affect the RAAS [see Warnings and Precautions (5.4, 5.5, 5.6)] . 
 The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated [see Contraindications (4)] . 

 Furosemide: Oral coadministration of aliskiren and furosemide reduced exposure to furosemide. Monitor diuretic effects when furosemide is coadministered with aliskiren. 

 Cyclosporine or Itraconazole: Avoid concomitant use. ( 5.7 , 7 , 12.3 ) 

 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of renal impairment and loss of antihypertensive effect. ( 7 )</Section>
</Text><Sentences>
<Sentence id="366" LabelDrug="Tekturna" section="34070-3">
<SentenceText>Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M3" type="Trigger" span="0 10" str="Do not use"/>
<Mention id="M2" type="Precipitant" span="34 5" str="ACEIs" code="N0000029130"/>
<Mention id="M4" type="Precipitant" span="26 4" str="ARBs" code="N0000000070"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M3" precipitant="M2"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M3" precipitant="M4"/>
</Sentence>
<Sentence id="366" LabelDrug="Tekturna" section="34070-3">
<SentenceText>Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M7" type="Trigger" span="0 10" str="Do not use"/>
<Mention id="M6" type="Precipitant" span="34 5" str="ACEIs" code="N0000029130"/>
<Mention id="M8" type="Precipitant" span="26 4" str="ARBs" code="N0000000070"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M7" precipitant="M6"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M7" precipitant="M8"/>
</Sentence>
<Sentence id="367" LabelDrug="Tekturna" section="34073-7">
<SentenceText>(5.7, 7, 12.3) Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of renal impairment and loss of antihypertensive effect.</SentenceText>
</Sentence>
<Sentence id="368" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Cyclosporine : Avoid coadministration of cyclosporine with aliskiren see Warnings and Precautions ( 5.7 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M9" type="Trigger" span="15 5" str="Avoid"/>
<Mention id="M10" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Interaction id="I5" type="Unspecified interaction" trigger="M9" precipitant="M10"/>
</Sentence>
<Sentence id="369" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Cyclosporine or Itraconazole: Avoid concomitant use.</SentenceText>
<Mention id="M13" type="Trigger" span="30 5" str="Avoid"/>
<Mention id="M12" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M14" type="Precipitant" span="16 12" str="Itraconazole" code="N0000006753"/>
<Interaction id="I6" type="Unspecified interaction" trigger="M13" precipitant="M12"/>
<Interaction id="I7" type="Unspecified interaction" trigger="M13" precipitant="M14"/>
</Sentence>
<Sentence id="369" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Cyclosporine or Itraconazole: Avoid concomitant use.</SentenceText>
<Mention id="M17" type="Trigger" span="30 5" str="Avoid"/>
<Mention id="M16" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M18" type="Precipitant" span="16 12" str="Itraconazole" code="N0000006753"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M17" precipitant="M16"/>
<Interaction id="I9" type="Unspecified interaction" trigger="M17" precipitant="M18"/>
</Sentence>
<Sentence id="370" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M31" type="Trigger" span="180 14" str="increased risk"/>
<Mention id="M20" type="Precipitant" span="144 5" str="ACEIs" code="N0000029130"/>
<Mention id="M33" type="SpecificInteraction" span="198 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M34" type="SpecificInteraction" span="211 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M35" type="SpecificInteraction" span="229 25" str=" changes in renal function " code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M36" type="SpecificInteraction" span="266 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M26" type="Precipitant" span="110 25" str="agents acting on the RAAS" code="NO MAP"/>
<Mention id="M32" type="Precipitant" span="153 4" str="ARBs" code="N0000000070"/>
<Interaction id="I10" type="Pharmacodynamic interaction" trigger="M31" precipitant="M20" effect="M33;M34;M35;M36"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M31" precipitant="M26" effect="M33;M34;M35;M36"/>
<Interaction id="I12" type="Pharmacodynamic interaction" trigger="M31" precipitant="M32" effect="M33;M34;M35;M36"/>
</Sentence>
<Sentence id="370" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M49" type="Trigger" span="180 14" str="increased risk"/>
<Mention id="M38" type="Precipitant" span="144 5" str="ACEIs" code="N0000029130"/>
<Mention id="M51" type="SpecificInteraction" span="198 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M52" type="SpecificInteraction" span="211 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M53" type="SpecificInteraction" span="229 25" str=" changes in renal function " code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M54" type="SpecificInteraction" span="266 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M44" type="Precipitant" span="110 25" str="agents acting on the RAAS" code="NO MAP"/>
<Mention id="M50" type="Precipitant" span="153 4" str="ARBs" code="N0000000070"/>
<Interaction id="I13" type="Pharmacodynamic interaction" trigger="M49" precipitant="M38" effect="M51;M52;M53;M54"/>
<Interaction id="I14" type="Pharmacodynamic interaction" trigger="M49" precipitant="M44" effect="M51;M52;M53;M54"/>
<Interaction id="I15" type="Pharmacodynamic interaction" trigger="M49" precipitant="M50" effect="M51;M52;M53;M54"/>
</Sentence>
<Sentence id="370" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M67" type="Trigger" span="180 14" str="increased risk"/>
<Mention id="M56" type="Precipitant" span="144 5" str="ACEIs" code="N0000029130"/>
<Mention id="M69" type="SpecificInteraction" span="198 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M70" type="SpecificInteraction" span="211 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M71" type="SpecificInteraction" span="229 25" str=" changes in renal function " code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M72" type="SpecificInteraction" span="266 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M62" type="Precipitant" span="110 25" str="agents acting on the RAAS" code="NO MAP"/>
<Mention id="M68" type="Precipitant" span="153 4" str="ARBs" code="N0000000070"/>
<Interaction id="I16" type="Pharmacodynamic interaction" trigger="M67" precipitant="M56" effect="M69;M70;M71;M72"/>
<Interaction id="I17" type="Pharmacodynamic interaction" trigger="M67" precipitant="M62" effect="M69;M70;M71;M72"/>
<Interaction id="I18" type="Pharmacodynamic interaction" trigger="M67" precipitant="M68" effect="M69;M70;M71;M72"/>
</Sentence>
<Sentence id="371" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Furosemide : Oral coadministration of aliskiren and furosemide reduced exposure to furosemide .</SentenceText>
<Mention id="M73" type="Trigger" span="63 19" str="reduced exposure to"/>
<Mention id="M74" type="Precipitant" span="52 10" str="furosemide" code="N0000007175"/>
<Interaction id="I19" type="Pharmacokinetic interaction" trigger="M73" precipitant="M74" effect="C54358"/>
</Sentence>
<Sentence id="372" LabelDrug="Tekturna" section="34073-7">
<SentenceText>In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with CrCl less than 60 mL/min .</SentenceText>
<Mention id="M77" type="Trigger" span="13 5" str="avoid"/>
<Mention id="M76" type="Precipitant" span="50 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M78" type="Precipitant" span="68 4" str="ARBs" code="N0000000070"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M77" precipitant="M76"/>
<Interaction id="I21" type="Unspecified interaction" trigger="M77" precipitant="M78"/>
</Sentence>
<Sentence id="372" LabelDrug="Tekturna" section="34073-7">
<SentenceText>In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with CrCl less than 60 mL/min .</SentenceText>
<Mention id="M81" type="Trigger" span="13 5" str="avoid"/>
<Mention id="M80" type="Precipitant" span="50 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M82" type="Precipitant" span="68 4" str="ARBs" code="N0000000070"/>
<Interaction id="I22" type="Unspecified interaction" trigger="M81" precipitant="M80"/>
<Interaction id="I23" type="Unspecified interaction" trigger="M81" precipitant="M82"/>
</Sentence>
<Sentence id="373" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Itraconazole : Avoid coadministration of itraconazole with aliskiren see Warnings and Precautions ( 5.7 ) and Clinical Pharmacology ( 12.3 ) .</SentenceText>
<Mention id="M83" type="Trigger" span="15 5" str="Avoid"/>
<Mention id="M84" type="Precipitant" span="41 12" str="itraconazole" code="N0000006753"/>
<Interaction id="I24" type="Unspecified interaction" trigger="M83" precipitant="M84"/>
</Sentence>
<Sentence id="374" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Monitor blood pressure , renal function , and electrolytes in patients taking aliskiren and other agents that affect the RAAS see Warnings and Precautions ( 5.4 , 5.5 , 5.6 ) .</SentenceText>
</Sentence>
<Sentence id="375" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Monitor diuretic effects when furosemide is coadministered with aliskiren .</SentenceText>
<Mention id="M85" type="Trigger" span="0 7" str="Monitor"/>
<Mention id="M86" type="Precipitant" span="30 10" str="furosemide" code="N0000007175"/>
<Interaction id="I25" type="Unspecified interaction" trigger="M85" precipitant="M86"/>
</Sentence>
<Sentence id="376" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Monitor renal function periodically in patients receiving aliskiren and NSAID therapy .</SentenceText>
<Mention id="M87" type="Trigger" span="0 7" str="Monitor"/>
<Mention id="M88" type="Precipitant" span="72 5" str="NSAID" code="N0000175722"/>
<Interaction id="I26" type="Unspecified interaction" trigger="M87" precipitant="M88"/>
</Sentence>
<Sentence id="377" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Most patients receiving the combination of two drugs that inhibit the renin-angiotensin system do not obtain any additional benefit compared to monotherapy.</SentenceText>
</Sentence>
<Sentence id="378" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs ( NSAIDs ) including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) : In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors with agents that affect the RAAS , including aliskiren , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M93" type="Trigger" span="367 13" str="may result in"/>
<Mention id="M90" type="Precipitant" span="39 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M95" type="SpecificInteraction" span="381 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M96" type="SpecificInteraction" span="434 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M94" type="Precipitant" span="283 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I27" type="Pharmacodynamic interaction" trigger="M93" precipitant="M90" effect="M95;M96"/>
<Interaction id="I28" type="Pharmacodynamic interaction" trigger="M93" precipitant="M94" effect="M95;M96"/>
</Sentence>
<Sentence id="378" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs ( NSAIDs ) including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) : In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors with agents that affect the RAAS , including aliskiren , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M101" type="Trigger" span="367 13" str="may result in"/>
<Mention id="M98" type="Precipitant" span="39 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M103" type="SpecificInteraction" span="381 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M104" type="SpecificInteraction" span="434 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M102" type="Precipitant" span="283 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I29" type="Pharmacodynamic interaction" trigger="M101" precipitant="M98" effect="M103;M104"/>
<Interaction id="I30" type="Pharmacodynamic interaction" trigger="M101" precipitant="M102" effect="M103;M104"/>
</Sentence>
<Sentence id="379" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M117" type="Trigger" span="354 10" str="may result"/>
<Mention id="M106" type="Precipitant" span="95 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M119" type="SpecificInteraction" span="368 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M120" type="SpecificInteraction" span="420 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M110" type="Precipitant" span="66 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M114" type="Precipitant" span="0 36" str="Nonsteroidal Anti-Inflammatory Drugs" code="n0000175722"/>
<Mention id="M118" type="Precipitant" span="38 6" str="NSAIDs" code="N0000175722"/>
<Interaction id="I31" type="Pharmacodynamic interaction" trigger="M117" precipitant="M106" effect="M119;M120"/>
<Interaction id="I32" type="Pharmacodynamic interaction" trigger="M117" precipitant="M110" effect="M119;M120"/>
<Interaction id="I33" type="Pharmacodynamic interaction" trigger="M117" precipitant="M114" effect="M119;M120"/>
<Interaction id="I34" type="Pharmacodynamic interaction" trigger="M117" precipitant="M118" effect="M119;M120"/>
</Sentence>
<Sentence id="379" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M133" type="Trigger" span="354 10" str="may result"/>
<Mention id="M122" type="Precipitant" span="95 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M135" type="SpecificInteraction" span="368 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M136" type="SpecificInteraction" span="420 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M126" type="Precipitant" span="66 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M130" type="Precipitant" span="0 36" str="Nonsteroidal Anti-Inflammatory Drugs" code="n0000175722"/>
<Mention id="M134" type="Precipitant" span="38 6" str="NSAIDs" code="N0000175722"/>
<Interaction id="I35" type="Pharmacodynamic interaction" trigger="M133" precipitant="M122" effect="M135;M136"/>
<Interaction id="I36" type="Pharmacodynamic interaction" trigger="M133" precipitant="M126" effect="M135;M136"/>
<Interaction id="I37" type="Pharmacodynamic interaction" trigger="M133" precipitant="M130" effect="M135;M136"/>
<Interaction id="I38" type="Pharmacodynamic interaction" trigger="M133" precipitant="M134" effect="M135;M136"/>
</Sentence>
<Sentence id="379" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M149" type="Trigger" span="354 10" str="may result"/>
<Mention id="M138" type="Precipitant" span="95 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M151" type="SpecificInteraction" span="368 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M152" type="SpecificInteraction" span="420 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M142" type="Precipitant" span="66 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M146" type="Precipitant" span="0 36" str="Nonsteroidal Anti-Inflammatory Drugs" code="n0000175722"/>
<Mention id="M150" type="Precipitant" span="38 6" str="NSAIDs" code="N0000175722"/>
<Interaction id="I39" type="Pharmacodynamic interaction" trigger="M149" precipitant="M138" effect="M151;M152"/>
<Interaction id="I40" type="Pharmacodynamic interaction" trigger="M149" precipitant="M142" effect="M151;M152"/>
<Interaction id="I41" type="Pharmacodynamic interaction" trigger="M149" precipitant="M146" effect="M151;M152"/>
<Interaction id="I42" type="Pharmacodynamic interaction" trigger="M149" precipitant="M150" effect="M151;M152"/>
</Sentence>
<Sentence id="379" LabelDrug="Tekturna" section="34073-7">
<SentenceText>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M165" type="Trigger" span="354 10" str="may result"/>
<Mention id="M154" type="Precipitant" span="95 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M167" type="SpecificInteraction" span="368 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M168" type="SpecificInteraction" span="420 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M158" type="Precipitant" span="66 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M162" type="Precipitant" span="0 36" str="Nonsteroidal Anti-Inflammatory Drugs" code="n0000175722"/>
<Mention id="M166" type="Precipitant" span="38 6" str="NSAIDs" code="N0000175722"/>
<Interaction id="I43" type="Pharmacodynamic interaction" trigger="M165" precipitant="M154" effect="M167;M168"/>
<Interaction id="I44" type="Pharmacodynamic interaction" trigger="M165" precipitant="M158" effect="M167;M168"/>
<Interaction id="I45" type="Pharmacodynamic interaction" trigger="M165" precipitant="M162" effect="M167;M168"/>
<Interaction id="I46" type="Pharmacodynamic interaction" trigger="M165" precipitant="M166" effect="M167;M168"/>
</Sentence>
<Sentence id="380" LabelDrug="Tekturna" section="34073-7">
<SentenceText>The antihypertensive effect of aliskiren may be attenuated by NSAIDs .</SentenceText>
<Mention id="M169" type="Trigger" span="21 6;48 10" str="effect | attenuated"/>
<Mention id="M170" type="Precipitant" span="62 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M171" type="SpecificInteraction" span="4 23;48 10" str="antihypertensive effect | attenuated" code="NO MAP"/>
<Interaction id="I47" type="Pharmacodynamic interaction" trigger="M169" precipitant="M170" effect="M171"/>
</Sentence>
<Sentence id="381" LabelDrug="Tekturna" section="34073-7">
<SentenceText>The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated [see Contraindications (4)].</SentenceText>
<Mention id="M174" type="Trigger" span="80 15" str="contraindicated"/>
<Mention id="M173" type="Precipitant" span="51 4" str="ACEI" code="N0000029130"/>
<Mention id="M175" type="Precipitant" span="41 3" str="ARB" code="n0000175561"/>
<Interaction id="I48" type="Unspecified interaction" trigger="M174" precipitant="M173"/>
<Interaction id="I49" type="Unspecified interaction" trigger="M174" precipitant="M175"/>
</Sentence>
<Sentence id="381" LabelDrug="Tekturna" section="34073-7">
<SentenceText>The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated [see Contraindications (4)].</SentenceText>
<Mention id="M178" type="Trigger" span="80 15" str="contraindicated"/>
<Mention id="M177" type="Precipitant" span="51 4" str="ACEI" code="N0000029130"/>
<Mention id="M179" type="Precipitant" span="41 3" str="ARB" code="n0000175561"/>
<Interaction id="I50" type="Unspecified interaction" trigger="M178" precipitant="M177"/>
<Interaction id="I51" type="Unspecified interaction" trigger="M178" precipitant="M179"/>
</Sentence>
<Sentence id="382" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Avoid concomitant use of aliskiren with cyclosporine or itraconazole see Drug Interactions ( 7 ) .</SentenceText>
<Mention id="M182" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M181" type="Precipitant" span="40 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M183" type="Precipitant" span="56 12" str="itraconazole" code="N0000006753"/>
<Interaction id="I52" type="Unspecified interaction" trigger="M182" precipitant="M181"/>
<Interaction id="I53" type="Unspecified interaction" trigger="M182" precipitant="M183"/>
</Sentence>
<Sentence id="382" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Avoid concomitant use of aliskiren with cyclosporine or itraconazole see Drug Interactions ( 7 ) .</SentenceText>
<Mention id="M186" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M185" type="Precipitant" span="40 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M187" type="Precipitant" span="56 12" str="itraconazole" code="N0000006753"/>
<Interaction id="I54" type="Unspecified interaction" trigger="M186" precipitant="M185"/>
<Interaction id="I55" type="Unspecified interaction" trigger="M186" precipitant="M187"/>
</Sentence>
<Sentence id="383" LabelDrug="Tekturna" section="43685-7">
<SentenceText>In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with creatinine clearance ( CrCl ) less than 60 mL/min see Contraindications ( 4 ) , Drug Interactions ( 7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M190" type="Trigger" span="13 5" str="avoid"/>
<Mention id="M189" type="Precipitant" span="50 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M191" type="Precipitant" span="68 4" str="ARBs" code="N0000000070"/>
<Interaction id="I56" type="Unspecified interaction" trigger="M190" precipitant="M189"/>
<Interaction id="I57" type="Unspecified interaction" trigger="M190" precipitant="M191"/>
</Sentence>
<Sentence id="383" LabelDrug="Tekturna" section="43685-7">
<SentenceText>In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with creatinine clearance ( CrCl ) less than 60 mL/min see Contraindications ( 4 ) , Drug Interactions ( 7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M194" type="Trigger" span="13 5" str="avoid"/>
<Mention id="M193" type="Precipitant" span="50 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M195" type="Precipitant" span="68 4" str="ARBs" code="N0000000070"/>
<Interaction id="I58" type="Unspecified interaction" trigger="M194" precipitant="M193"/>
<Interaction id="I59" type="Unspecified interaction" trigger="M194" precipitant="M195"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M211" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M197" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M213" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M200" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M203" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M206" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M209" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M212" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I60" type="Pharmacodynamic interaction" trigger="M211" precipitant="M197" effect="M213"/>
<Interaction id="I61" type="Pharmacodynamic interaction" trigger="M211" precipitant="M200" effect="M213"/>
<Interaction id="I62" type="Pharmacodynamic interaction" trigger="M211" precipitant="M203" effect="M213"/>
<Interaction id="I63" type="Pharmacodynamic interaction" trigger="M211" precipitant="M206" effect="M213"/>
<Interaction id="I64" type="Pharmacodynamic interaction" trigger="M211" precipitant="M209" effect="M213"/>
<Interaction id="I65" type="Pharmacodynamic interaction" trigger="M211" precipitant="M212" effect="M213"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M229" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M215" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M231" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M218" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M221" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M224" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M227" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M230" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I66" type="Pharmacodynamic interaction" trigger="M229" precipitant="M215" effect="M231"/>
<Interaction id="I67" type="Pharmacodynamic interaction" trigger="M229" precipitant="M218" effect="M231"/>
<Interaction id="I68" type="Pharmacodynamic interaction" trigger="M229" precipitant="M221" effect="M231"/>
<Interaction id="I69" type="Pharmacodynamic interaction" trigger="M229" precipitant="M224" effect="M231"/>
<Interaction id="I70" type="Pharmacodynamic interaction" trigger="M229" precipitant="M227" effect="M231"/>
<Interaction id="I71" type="Pharmacodynamic interaction" trigger="M229" precipitant="M230" effect="M231"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M247" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M233" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M249" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M236" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M239" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M242" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M245" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M248" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I72" type="Pharmacodynamic interaction" trigger="M247" precipitant="M233" effect="M249"/>
<Interaction id="I73" type="Pharmacodynamic interaction" trigger="M247" precipitant="M236" effect="M249"/>
<Interaction id="I74" type="Pharmacodynamic interaction" trigger="M247" precipitant="M239" effect="M249"/>
<Interaction id="I75" type="Pharmacodynamic interaction" trigger="M247" precipitant="M242" effect="M249"/>
<Interaction id="I76" type="Pharmacodynamic interaction" trigger="M247" precipitant="M245" effect="M249"/>
<Interaction id="I77" type="Pharmacodynamic interaction" trigger="M247" precipitant="M248" effect="M249"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M265" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M251" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M267" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M254" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M257" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M260" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M263" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M266" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I78" type="Pharmacodynamic interaction" trigger="M265" precipitant="M251" effect="M267"/>
<Interaction id="I79" type="Pharmacodynamic interaction" trigger="M265" precipitant="M254" effect="M267"/>
<Interaction id="I80" type="Pharmacodynamic interaction" trigger="M265" precipitant="M257" effect="M267"/>
<Interaction id="I81" type="Pharmacodynamic interaction" trigger="M265" precipitant="M260" effect="M267"/>
<Interaction id="I82" type="Pharmacodynamic interaction" trigger="M265" precipitant="M263" effect="M267"/>
<Interaction id="I83" type="Pharmacodynamic interaction" trigger="M265" precipitant="M266" effect="M267"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M283" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M269" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M285" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M272" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M275" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M278" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M281" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M284" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I84" type="Pharmacodynamic interaction" trigger="M283" precipitant="M269" effect="M285"/>
<Interaction id="I85" type="Pharmacodynamic interaction" trigger="M283" precipitant="M272" effect="M285"/>
<Interaction id="I86" type="Pharmacodynamic interaction" trigger="M283" precipitant="M275" effect="M285"/>
<Interaction id="I87" type="Pharmacodynamic interaction" trigger="M283" precipitant="M278" effect="M285"/>
<Interaction id="I88" type="Pharmacodynamic interaction" trigger="M283" precipitant="M281" effect="M285"/>
<Interaction id="I89" type="Pharmacodynamic interaction" trigger="M283" precipitant="M284" effect="M285"/>
</Sentence>
<Sentence id="384" LabelDrug="Tekturna" section="43685-7">
<SentenceText>Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .</SentenceText>
<Mention id="M301" type="Trigger" span="359 9;380 4" str="may be at | risk"/>
<Mention id="M287" type="Precipitant" span="224 4" str="ACEI" code="N0000029130"/>
<Mention id="M303" type="SpecificInteraction" span="400 19" str="acute renal failure" code="14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M290" type="Precipitant" span="218 3" str="ARB" code="n0000175561"/>
<Mention id="M293" type="Precipitant" span="330 16" str="COX-2 inhibitors" code="N0000008288"/>
<Mention id="M296" type="Precipitant" span="300 27" str="Cyclooxygenase-2 inhibitors" code="n0000008288"/>
<Mention id="M299" type="Precipitant" span="232 35" str="nonsteroidal anti-inflammatory drug" code="n0000175722"/>
<Mention id="M302" type="Precipitant" span="270 5" str="NSAID" code="N0000175722"/>
<Interaction id="I90" type="Pharmacodynamic interaction" trigger="M301" precipitant="M287" effect="M303"/>
<Interaction id="I91" type="Pharmacodynamic interaction" trigger="M301" precipitant="M290" effect="M303"/>
<Interaction id="I92" type="Pharmacodynamic interaction" trigger="M301" precipitant="M293" effect="M303"/>
<Interaction id="I93" type="Pharmacodynamic interaction" trigger="M301" precipitant="M296" effect="M303"/>
<Interaction id="I94" type="Pharmacodynamic interaction" trigger="M301" precipitant="M299" effect="M303"/>
<Interaction id="I95" type="Pharmacodynamic interaction" trigger="M301" precipitant="M302" effect="M303"/>
</Sentence>
<Sentence id="385" LabelDrug="Tekturna" section="43685-7">
<SentenceText>When aliskiren was given with cyclosporine or itraconazole , the blood concentrations of aliskiren were significantly increased .</SentenceText>
<Mention id="M306" type="Trigger" span="65 20;118 9" str="blood concentrations | increased"/>
<Mention id="M305" type="Precipitant" span="30 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M307" type="Precipitant" span="46 12" str="itraconazole" code="N0000006753"/>
<Interaction id="I96" type="Pharmacokinetic interaction" trigger="M306" precipitant="M305" effect="C54355"/>
<Interaction id="I97" type="Pharmacokinetic interaction" trigger="M306" precipitant="M307" effect="C54355"/>
</Sentence>
<Sentence id="385" LabelDrug="Tekturna" section="43685-7">
<SentenceText>When aliskiren was given with cyclosporine or itraconazole , the blood concentrations of aliskiren were significantly increased .</SentenceText>
<Mention id="M310" type="Trigger" span="65 20;118 9" str="blood concentrations | increased"/>
<Mention id="M309" type="Precipitant" span="30 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M311" type="Precipitant" span="46 12" str="itraconazole" code="N0000006753"/>
<Interaction id="I98" type="Pharmacokinetic interaction" trigger="M310" precipitant="M309" effect="C54355"/>
<Interaction id="I99" type="Pharmacokinetic interaction" trigger="M310" precipitant="M311" effect="C54355"/>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="aceis" precipitantCode="N0000029130" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aceis" precipitantCode="N0000029130" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aceis" precipitantCode="N0000029130" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aceis" precipitantCode="N0000029130" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="aceis" precipitantCode="N0000029130"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="arbs" precipitantCode="N0000000070" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="arbs" precipitantCode="N0000000070" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="arbs" precipitantCode="N0000000070" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="arbs" precipitantCode="N0000000070" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="arbs" precipitantCode="N0000000070"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine" precipitantCode="N0000007346" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyclosporine" precipitantCode="N0000007346"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="itraconazole" precipitantCode="N0000006753" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="itraconazole" precipitantCode="N0000006753"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="agents acting on the raas" precipitantCode="NO MAP" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="agents acting on the raas" precipitantCode="NO MAP" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="agents acting on the raas" precipitantCode="NO MAP" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="agents acting on the raas" precipitantCode="NO MAP" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="furosemide" precipitantCode="N0000007175" effect="C54358"/>
<LabelInteraction type="Unspecified interaction" precipitant="furosemide" precipitantCode="N0000007175"/>
<LabelInteraction type="Unspecified interaction" precipitant="ace inhibitors" precipitantCode="N0000029130"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaid" precipitantCode="N0000175722" effect="14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="nsaid" precipitantCode="N0000175722"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cox-2 inhibitors" precipitantCode="N0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cox-2 inhibitors" precipitantCode="N0000008288" effect="14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cox-2 inhibitors" precipitantCode="N0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclooxygenase-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclooxygenase-2 inhibitors" precipitantCode="n0000008288" effect="14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclooxygenase-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nonsteroidal anti-inflammatory drugs" precipitantCode="n0000175722" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nonsteroidal anti-inflammatory drugs" precipitantCode="n0000175722" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="acei" precipitantCode="N0000029130" effect="14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="acei" precipitantCode="N0000029130"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="arb" precipitantCode="n0000175561" effect="14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="arb" precipitantCode="n0000175561"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nonsteroidal anti-inflammatory drug" precipitantCode="n0000175722" effect="14669001: Acute renal failure syndrome (disorder)"/>

</LabelInteractions></Label>